Brainstorm Health: Superbug Threat, Parkinson’s Smartwatch, Medical Pay Gap

AstraZeneca spikes after (finally) issuing positive earnings. Shares of British drug maker AstraZeneca rose more than 3.5% in Thursday trading as the pharma giant shared some solid financial news—and expressed, at long last, some legitimate optimism about the future. Quarterly sales rose 8%, buoyed by strong growth in cancer drug sales, and CEO Pascal Soriot said the company’s strategy of replacing older, patent-expiring medications with a pipeline of 10 new therapies has been successful. “Today marks an important day for the future of AstraZeneca, with the performance in the quarter and year to date showing what we expect will be the start of a period of sustained growth for years to come,” he said. (Reuters)